Cargando…

Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study

BACKGROUND: Radiosurgery is employed for the treatment of brain metastases. The aim of this study is to evaluate the efficacy and tolerability of single-dose radiosurgery (SRS) compared to hypofractionated stereotactic radiotherapy (hFSRT). MATERIALS AND METHODS: Between 2004 and 2018, we analyzed t...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Pinta, Carolina, Fernández-Lizarbe, E., Sevillano, D., Capúz, A. B., Martín, M., Hernanz, R., Vallejo, C., Sancho, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Whioce Publishing Pte. Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452725/
https://www.ncbi.nlm.nih.gov/pubmed/32875136
_version_ 1783575215193718784
author de la Pinta, Carolina
Fernández-Lizarbe, E.
Sevillano, D.
Capúz, A. B.
Martín, M.
Hernanz, R.
Vallejo, C.
Martín, M.
Sancho, S.
author_facet de la Pinta, Carolina
Fernández-Lizarbe, E.
Sevillano, D.
Capúz, A. B.
Martín, M.
Hernanz, R.
Vallejo, C.
Martín, M.
Sancho, S.
author_sort de la Pinta, Carolina
collection PubMed
description BACKGROUND: Radiosurgery is employed for the treatment of brain metastases. The aim of this study is to evaluate the efficacy and tolerability of single-dose radiosurgery (SRS) compared to hypofractionated stereotactic radiotherapy (hFSRT). MATERIALS AND METHODS: Between 2004 and 2018, we analyzed treatments of 97 patients with 135 brain metastases. Fifty-six patients were treated with SRS, and 41 patients were treated with hFSRT. Median dose was 16 Gy (12-20 Gy) for the SRS group and 30 Gy in 5-6 fractions for the hFSRT group. hFSRT was used for larger lesions and lesions located near critical structures. Kaplan-Meier curves were constructed for overall survival (OS) and local control (LC). RESULTS: Median age was 64 years (range, 32-89 years). Median survival was 10 months (1-68 months). With a median follow-up of 10 months, no significant differences in OS between groups were found (P=0.21). LC for all patients was 67%. Local progression-free survival (LPFS) at 6 months and 1 year was 71% and 60% for the SRS group, respectively, and 80% and 69% for the hFSRT group, respectively (P=0.93). Although hFSRT was used for larger lesions and lesions in adverse locations, LPFS was not inferior compared to lesions treated with SRS. We observed acute toxicity grade 1-2 in 25 patients (25.8%). Late complications were observed in 11 patients (11.3%). Acute and late toxicity was similar in the SRS- and hFSRT-treated patients (P=0.63 and P=0.11, respectively). Brain recurrence occurred in 37.5% and 14.6% in the hFSRT and SRS group, respectively (P=0.06). CONCLUSIONS: Since patients treated with hFSRT exhibited similar survival and LPFS rates without differences in toxicity compared to those treated with SRS, hFSRT can be beneficial, particularly for patients with brain metastases. RELEVANCE FOR PATIENTS: Hypofractionated schemes in stereotactic radiosurgery offers treatment alternatives to patients with large lesions or lesions near critical structures.
format Online
Article
Text
id pubmed-7452725
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Whioce Publishing Pte. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-74527252020-08-31 Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study de la Pinta, Carolina Fernández-Lizarbe, E. Sevillano, D. Capúz, A. B. Martín, M. Hernanz, R. Vallejo, C. Martín, M. Sancho, S. J Clin Transl Res Original Article BACKGROUND: Radiosurgery is employed for the treatment of brain metastases. The aim of this study is to evaluate the efficacy and tolerability of single-dose radiosurgery (SRS) compared to hypofractionated stereotactic radiotherapy (hFSRT). MATERIALS AND METHODS: Between 2004 and 2018, we analyzed treatments of 97 patients with 135 brain metastases. Fifty-six patients were treated with SRS, and 41 patients were treated with hFSRT. Median dose was 16 Gy (12-20 Gy) for the SRS group and 30 Gy in 5-6 fractions for the hFSRT group. hFSRT was used for larger lesions and lesions located near critical structures. Kaplan-Meier curves were constructed for overall survival (OS) and local control (LC). RESULTS: Median age was 64 years (range, 32-89 years). Median survival was 10 months (1-68 months). With a median follow-up of 10 months, no significant differences in OS between groups were found (P=0.21). LC for all patients was 67%. Local progression-free survival (LPFS) at 6 months and 1 year was 71% and 60% for the SRS group, respectively, and 80% and 69% for the hFSRT group, respectively (P=0.93). Although hFSRT was used for larger lesions and lesions in adverse locations, LPFS was not inferior compared to lesions treated with SRS. We observed acute toxicity grade 1-2 in 25 patients (25.8%). Late complications were observed in 11 patients (11.3%). Acute and late toxicity was similar in the SRS- and hFSRT-treated patients (P=0.63 and P=0.11, respectively). Brain recurrence occurred in 37.5% and 14.6% in the hFSRT and SRS group, respectively (P=0.06). CONCLUSIONS: Since patients treated with hFSRT exhibited similar survival and LPFS rates without differences in toxicity compared to those treated with SRS, hFSRT can be beneficial, particularly for patients with brain metastases. RELEVANCE FOR PATIENTS: Hypofractionated schemes in stereotactic radiosurgery offers treatment alternatives to patients with large lesions or lesions near critical structures. Whioce Publishing Pte. Ltd. 2020-07-08 /pmc/articles/PMC7452725/ /pubmed/32875136 Text en Copyright: © Whioce Publishing Pte. Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This work is licensed under a Creative Commons Attribution 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
de la Pinta, Carolina
Fernández-Lizarbe, E.
Sevillano, D.
Capúz, A. B.
Martín, M.
Hernanz, R.
Vallejo, C.
Martín, M.
Sancho, S.
Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study
title Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study
title_full Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study
title_fullStr Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study
title_full_unstemmed Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study
title_short Brain metastases: Single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: A retrospective study
title_sort brain metastases: single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: a retrospective study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452725/
https://www.ncbi.nlm.nih.gov/pubmed/32875136
work_keys_str_mv AT delapintacarolina brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT fernandezlizarbee brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT sevillanod brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT capuzab brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT martinm brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT hernanzr brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT vallejoc brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT martinm brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy
AT sanchos brainmetastasessingledoseradiosurgeryversushypofractionatedstereotacticradiotherapyaretrospectivestudy